Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases

被引：0
|
作者：
Cui, Dejun [1 ]
Hu, Mei [2 ]
Zhao, Xun [3 ]
机构：
[1] Guizhou Med Univ, Affiliated Peoples Hosp, Dept Gastroenterol, Guiyang, Guizhou Provinc, Peoples R China
[2] Guizhou Med Univ, Guiyang, Guizhou Provinc, Peoples R China
[3] Guizhou Med Univ, Affiliated Peoples Hosp, Div Gastroenterol & Hepatol, Guiyang, Guizhou Provinc, Peoples R China
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 14卷 / 10期
关键词：
ULCERATIVE-COLITIS;
D O I：
10.1016/j.cgh.2016.04.029
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1509 / 1509
页数：1
相关论文
共 50 条
  • [21] Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases
    Aden, Konrad
    Rehman, Ateequr
    Waschina, Silvio
    Pan, Wei-Hung
    Walker, Alesia
    Lucio, Marianna
    Nunez, Alejandro Mena
    Bharti, Richa
    Zimmerman, Johannes
    Bethge, Johannes
    Schulte, Berenice
    Schulte, Dominik
    Franke, Andre
    Nikolaus, Susanna
    Schroeder, Johann Oltmann
    Vandeputte, Doris
    Raes, Jeroen
    Szymczak, Silke
    Waetzig, Georg H.
    Zeuner, Rainald
    Schmitt-Kopplin, Philippe
    Kaleta, Christoph
    Schreiber, Stefan
    Rosenstiel, Philip
    GASTROENTEROLOGY, 2019, 157 (05) : 1279 - +
  • [22] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Reply
    Bouguen, Guillaume
    Brunet, Tanguy
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 855 - 856
  • [23] Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases
    Cheng, David
    Kochar, Bharati D.
    Cai, Tianxi
    Ananthakrishnan, Ashwin N.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2366 - +
  • [24] Expression of epithelial growth factor receptor, tumor necrosis factor-α and nuclear factor κB in inflammatory bowel diseases
    Durko, Lukasz
    Stasikowska-Kanicka, Olga
    Wagrowska-Danilewicz, Malgorzata
    Danilewicz, Marian
    Malecka-Panas, Ewa
    PRZEGLAD GASTROENTEROLOGICZNY, 2013, 8 (04): : 262 - 267
  • [25] Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
    Grijalva, Carlos G.
    Chen, Lang
    Delzell, Elizabeth
    Baddley, John W.
    Beukelman, Timothy
    Winthrop, Kevin L.
    Griffin, Marie R.
    Herrinton, Lisa J.
    Liu, Liyan
    Ouellet-Hellstrom, Rita
    Patkar, Nivedita M.
    Solomon, Daniel H.
    Lewis, James D.
    Xie, Fenglong
    Saag, Kenneth G.
    Curtis, Jeffrey R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21): : 2331 - 2339
  • [26] Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Ferrante, Marc
    Gils, Ann
    Cheifetz, Adam S.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) : 1510 - 1515
  • [27] Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out
    Agrawal, Manasi
    Dubinsky, Marla C.
    Colombela, Jean-Frederic
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (08): : 1035 - 1036
  • [28] Tumor necrosis factor-α antagonists and neuropathy
    Stuebgen, Joerg-Patrick
    MUSCLE & NERVE, 2008, 37 (03) : 281 - 292
  • [29] Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2019, 157 (04) : 922 - 924
  • [30] CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY ASSOCIATED WITH TUMOR NECROSIS FACTOR-α ANTAGONISTS
    Alshekhlee, Amer
    Basiri, Kevian
    Miles, J. Douglas
    Ahmad, Saef A.
    Katirji, Bashar
    MUSCLE & NERVE, 2010, 41 (05) : 723 - 727
12345